Peer Review Committee for Cancer Detection and Progression (CDP)

Areas Reviewed

  • Biomarker identification and pre-clinical development, including liquid biopsy and molecular imaging
  • Pre-clinical modeling to identify factors (such as microbiota, pathogens, nutrition, metabolism, oxygen levels, oncogenes, and tumor suppressor genes) and their mechanisms of action contributing to cancer progression
  • Mechanisms of therapeutic response, including tumor evolution and treatment resistance
  • Mechanisms of treatment-associated morbidities

Committee members are being determined and will be announced in 2021.